News

Unlocking the Future: Calamos's Innovative Bitcoin ETFs

Unlocking the Future: Calamos's Innovative Bitcoin ETFs

Calamos Investments Introduces Innovative Bitcoin ETFs

Calamos Investments LLC, a prominent player in the alternatives management industry, has made headlines with the launch of its latest Bitcoin Structured Alt Protection ETFs. These new ETFs are designed to offer investors an opportunity to engage with the world of Bitcoin while ensuring significant downside protection. This innovative approach blends traditional finance with digital assets, providing a safe pathway for investors looking to explore Bitcoin's potential.

Understanding the New ETFs

The newly introduced ETFs include the Calamos Bitcoin Structured Alt Protection ETF (CBOY), the Calamos Bitcoin 90 Series Structured Alt Protection ETF (CBXY), and the Calamos Bitcoin 80 Series Structured Alt Protection ETF (CBTY). Each of these ETFs provides a structured approach to investing in Bitcoin with varying levels of downside protection.

Investment Protection Features

What sets these ETFs apart is their built-in downside protection. The CBOY offers 100% downside protection, making it ideal for conservative investors. Meanwhile, the CBXY and CBTY provide 90% and 80% downside protection, respectively, with potentially higher returns. Here’s a quick overview of their cap rates:

  • CBOY: Initial cap rate of 10.00%
  • CBXY: Initial cap rate of 24.70%
  • CBTY: Initial cap rate of 41.05%

Trading and Management

The ETFs are overseen by Co-CIO Eli Pars and his experienced Alternatives Team. Their trading commenced recently, marking a significant milestone for Calamos Investments. Structured Protection ETFs reset on an annual basis, which means investors can enjoy refreshed cap rates every year, enhancing their investment strategy over time.

Benefits of Structured Protection ETFs

One of the advantages of investing in these Structured Protection ETFs is the ability to hold shares long term. Investors who maintain their investment for over a year may benefit from tax advantages since gains can grow in a tax-deferred manner at long-term capital gains rates. This positions investors to maximize their returns while enjoying protection against market volatility.

Calamos's Comprehensive Investment Approach

The suite of Structured Protection ETFs from Calamos is unique in the market, allowing financial advisors and investors to tap into capital-protected growth strategies. By offering exposure to significant US equity benchmarks alongside Bitcoin, these ETFs present a well-rounded option for those looking to diversify their portfolios within structured parameters.

About Calamos Investments

Calamos Investments is a renowned global investment firm with a diverse range of investment strategies. The firm’s offerings include multi-asset strategies, alternatives, convertible securities, fixed income, and more. With assets under management exceeding $40 billion, including over $18 billion in liquid alternatives as of a recent date, Calamos is dedicated to providing valuable investment solutions tailored for various clients, from financial advisors to individual investors.

Headquartered in the greater Chicago area, Calamos operates additional offices across key US locations, ensuring broad expertise and accessibility for its clients. The firm's commitment to innovation and excellence continues to distinguish it in the investment landscape.

Frequently Asked Questions

What are the new ETFs launched by Calamos Investments?

The new ETFs include Calamos Bitcoin Structured Alt Protection ETF (CBOY), Calamos Bitcoin 90 Series Structured Alt Protection ETF (CBXY), and Calamos Bitcoin 80 Series Structured Alt Protection ETF (CBTY).

What levels of downside protection do the ETFs offer?

CBOY offers 100% downside protection, CBXY provides 90% protection, and CBTY offers 80% downside protection, enabling various risk profiles for investors.

Who manages the Calamos Bitcoin ETFs?

The ETFs are managed by Co-CIO Eli Pars and the Alternatives Team, ensuring experienced oversight of the investment strategies.

What is the potential tax benefit of these ETFs?

Investors holding shares for longer than one year can experience tax-deferred growth on potential gains at long-term capital gains rates, presenting a significant tax advantage.

How does Calamos Investments stand out in the investment industry?

Calamos Investments is recognized for its diverse range of innovative investment strategies, comprehensive offerings in alternatives, and commitment to client success, setting it apart in the alternatives management space.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading